FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/04/2025
Back to search
Official data from USPTO
OLIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
45
Latest update
01/05/2025
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
12/24/2021
Registration date
07/09/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/09/2024
Last transaction
01/05/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
KR
Examiner
CLARKE, NANCY
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
OliX Pharmaceuticals, Inc.
Representatives
Joesph A. R. Gerber Knobbe, Martens, Olson & Bear, LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Dietary supplements; nucleic acid sequences for medical purposes; cultures of microorganisms for medical use; biotechnological preparations for medical usecellsrecombinant DNA sequencessynthetic RNA sequencesoligonucleotides for use in treating and repairing damaged human tissue through tissue nanotransfection (TNT); reagent paper for medical purposes; drugs for medical purposescardiovascular pharmaceuticalsanti-diabetic pharmaceuticalsmetabolic pharmaceuticalsantibacterial pharmaceuticalsmacular degeneration treatment pharmaceuticals (or ophthalmic pharmaceuticals)hair loss treatment pharmaceuticalshepatitis treatment pharmaceuticalsrespiratory disease treatment pharmaceuticalsneurological disease treatment pharmaceuticalshepatological disease treatment pharmaceuticals; synthetic peptides for the treatment of metabolicophthalmiccardiovascularpulmonaryhepatologicalrespiratoryneurological diseases and disorders; cardiovascular pharmaceuticalsanti-diabetic pharmaceuticalsantibacterial pharmaceuticalsmacular degeneration treatment pharmaceuticals (or ophthalmic pharmaceuticals)hair loss treatment pharmaceuticalshepatitis treatment pharmaceuticalsrespiratory disease treatment pharmaceuticalsneurological disease treatment pharmaceuticalshepatological disease treatment pharmaceuticals; materials for dental fillings; colostral antibodies for medical purposesmonoclonal antibodies for medical purposeshybrid antibodies for medical purposes; all the foregoing for human use and excluding goods related to the care and feeding of animals and plants
Class 42
Product research and development in the field of biotech technology; scientific research in the field of biotechnologymedical research in the field of biotechnology; scientific research and scientific investigations for medical purposes in the field of biomedicine; scientific research consultation and providing scientific research information both of the foregoing in the field of biomedicine; bacteriological research; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; pharmaceutical research services; scientific research in the field of genetics; medical research laboratory services; Scientific research and scientific investigations for medical purposesboth of the foregoing in the fields of medicinehealth and pharmacology; medical research; All the above-mentioned services excluding services related to the care and feeding of animals and plants
Publications
History of USPTO decisions and trademark events.
45 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/13/2024
FIMP
FINAL DISPOSITION PROCESSED
12/13/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/09/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/09/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
07/09/2024
GPNX
NOTIFICATION PROCESSED BY IB
04/29/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/23/2024
PUBO
PUBLISHED FOR OPPOSITION
04/23/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/10/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/10/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/03/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/07/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/06/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/06/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/13/2024
GNS1
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
01/08/2024
GNCF
CONTINUATION OF FINAL REFUSAL E-MAILED
01/08/2024
CNCF
ACTION CONTINUING A FINAL - COMPLETED
01/08/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/27/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/27/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/22/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/21/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
11/21/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/24/2023
GNFR
FINAL REFUSAL E-MAILED
05/24/2023
CNFR
FINAL REFUSAL WRITTEN
05/24/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/02/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/02/2023
ATRV
ATTORNEY REVIEW COMPLETED
02/01/2023
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
01/12/2023
RFNT
REFUSAL PROCESSED BY IB
01/04/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/12/2022
RFRR
REFUSAL PROCESSED BY MPU
12/12/2022
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
10/28/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
10/01/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/29/2022
CNRT
NON-FINAL ACTION WRITTEN
09/28/2022
DOCK
ASSIGNED TO EXAMINER
09/28/2022
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
07/23/2022
MAFR
APPLICATION FILING RECEIPT MAILED
03/15/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/10/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/03/2022
Continuous trademark protection
Get notified about every new filing that threatens OLIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.